Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The methamphetamine experience: a NIDA partnership.

Glen R Hanson1, Kristi S Rau, Annette E Fleckenstein

  • 1Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Room 112, Salt Lake City, UT 84112, USA. glen.hanson@hsc.utah.edu

Neuropharmacology
|October 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methcathinone self-administration decreases dopamine and serotonin transporter function in rats.

Drug and alcohol dependence·2026
Same author

Trail Making Test performance in early abstinence from methamphetamine: human evidence for a drug-associated Parkinsonian-like phenotype.

Frontiers in psychiatry·2026
Same author

Differential Effects of Neurotensin NTS1 and NTS2 Receptors on Locomotion.

Brain and behavior·2025
Same author

Methcathinone decreases dopamine transporter function: Role of protein kinase C.

Journal of neurochemistry·2021
Same author

3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters.

The Journal of pharmacology and experimental therapeutics·2020
Same author

Comprehensive oral care improves treatment outcomes in male and female patients with high-severity and chronic substance use disorders.

Journal of the American Dental Association (1939)·2019

Methamphetamine (METH) and MDMA damage brain dopamine and serotonin neurons, similar to Parkinson's disease. This neurotoxicity involves reactive oxygen species and monoamine transporters, offering insights into neurodegenerative disorders.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Toxicology

Background:

  • Amphetamine neurotoxicity, including methamphetamine (METH), was recognized in the 1970s.
  • Human neurotoxic effects of METH were confirmed over 20 years later.
  • METH-induced neurotoxicity shares similarities with Parkinson's disease pathology.

Purpose of the Study:

  • To investigate the neurotoxic properties of amphetamines like METH and MDMA.
  • To elucidate the mechanisms underlying amphetamine-induced damage to dopamine and serotonin neurons.
  • To understand the role of monoamine transporters and reactive oxygen species in amphetamine neurotoxicity.

Main Methods:

  • Review of pharmacological and neurotoxicological studies on amphetamines.
  • Analysis of METH's selective damage to the nigrostriatal dopamine (DA) projection.

Related Experiment Videos

  • Examination of METH and MDMA effects on central nervous system (CNS) serotonin neurons.

    • Main Results:

    • High-dose METH selectively damages the nigrostriatal DA projection, linked to intracellular DA accumulation and reactive oxygen species (ROS).
    • Dopamine plasmalemmal transporter and vesicular monoamine transporter-2 are critical in METH neurotoxicity.
    • METH and MDMA also damage CNS serotonin neurons, with mechanisms involving ROS and monoamine transporters.

    Conclusions:

    • Amphetamine neurotoxicity research illuminates monoamine regulation.
    • Understanding amphetamine's effects enhances knowledge of neurodegenerative diseases like Parkinson's.
    • Monoamine transporters and ROS are key factors in amphetamine-induced neurotoxicity.